ReviewJournal of Zhejiang University. Science. B2026
Pulmonary sclerosing pneumocytoma with lymph node metastasis and high
Review in Journal of Zhejiang University. Science. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Symptomatic Sclerosing Pneumocytoma of Lung: A Diagnostic Challenge with Diverse Morphological Patterns.Iranian journal of pathology · 2026Article
- [Diagnosis and Intraoperative Decision-making in Pulmonary Sclerosing Pneumocytoma with Atypical Imaging Findings: A Case Report and Review of the Literature].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Analysis of the clinicopathological characteristics of pulmonary sclerosing pneumocytoma (PSP).Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pulmonary sclerosing pneumocytoma (PSP) was first reported by Liebow and Hubbell (1956). It was initially called pulmonary sclerosing hemangioma (PSH) because it was thought to be derived from endothelial cells with rich vascularity. However, the 2015 World Health Organization Classification of Lung Tumors removed the term "sclerosing hemangioma," since these tumors lack vascular origin (Travis et al., 2015), and the renamed tumor was considered a rare and benign lung tumor. However, several reports have described PSP with lymph node metastasis (Soo et al., 2017). Thus, PSP is not always benign and has the potential to metastasize. PSP shows varying levels of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.